During expiration, the alveolar air-liquid interface would otherwise create conditions that favor greater surface tension. Pulmonary surfactant lowers that tension during this phase, helping alveoli remain stable rather than collapse. This stabilization reduces the effort required to move air, making surfactant action essential for maintaining effective breathing across the respiratory cycle.
Phospholipids and specialized proteins form the pulmonary surfactant mixture that operates at the alveolar air-liquid interface. This composition enables the lining layer to modify interfacial tension efficiently. Their combined presence is therefore relevant to alveolar stability and respiratory mechanics, rather than surfactant function being attributable to a single molecular component.
When surfactant is inadequate, alveolar stability is compromised, promoting collapse and impairing gas exchange. The resulting problem is not limited to the interface itself: reduced stability also increases the work required for breathing. This connection helps explain why disorders involving insufficient surfactant can produce both ineffective oxygen transfer and greater respiratory effort.
Surfactant replacement therapy is particularly relevant for premature infants with respiratory distress syndrome, where inadequate surfactant contributes to pulmonary dysfunction. It is used in selected patients rather than as a universal treatment. Its clinical rationale is to restore surface-active function at the alveolar interface, addressing a mechanism that can worsen collapse and gas-exchange impairment.
In selected patients, replacement therapy can improve lung compliance and oxygenation. These outcomes reflect two important aspects of respiratory performance: how effectively the lungs function during breathing and how well oxygen transfer occurs. Monitoring such changes helps indicate whether restoring surfactant function has benefited the patient's pulmonary condition.
Surfactant action links events at the alveolar air-liquid interface with clinically important respiratory outcomes. Changes in this process can be associated with alveolar collapse, impaired gas exchange, and increased work of breathing. This connection explains why lung compliance and oxygenation are relevant outcomes when clinicians evaluate disorders involving surfactant or consider replacement therapy.